Samsung Biologics Injects 520 Billion Won into U.S. Subsidiary Through Capital Increase

Samsung Biologics announces 520 billion won capital injection into its U.S. subsidiary to fund acquisition of Human Genome Sciences' biopharmaceutical production facility in Rockville, Maryland, through shareholder allocation with record date set for the 27th.